Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062166 · ClinicalTrials.gov registry record
Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 340
- Enrollment target
NCT00062166: Completed study, sponsored by National Cancer Institute (NCI).
NCT00062166 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 340 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00062166 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 340 participants
- Enrollment target
Study Summary
Von Hippel-Lindau disease (VHL) is an inherited cancer syndrome. Patients are at risk for developing pancreatic cysts and tumors. These tumors are more aggressive in some people than in others. To learn more about this disease, its genetic cause and how best to treat it, this study will 1) identify patients with VHL who have pancreatic lesions; 2) examine the characteristics of the lesions and how fast they grow; 3) study how well imaging tests can reveal lesion characteristics that will help in diagnosis; and 4) perform genetic studies using blood and, when possible, tissue samples. Patients 12 years of age and older with VHL involving the pancreas may be eligible for this study. Participants will undergo some or all of the following tests and procedures: * Interviews with a cancer doctor, cancer nurses, and a surgeon (if surgery is recommended). * Computed tomography (CT) scan of the abdomen, chest, or pelvis. This test uses x-rays to produce images of body tissues and organs in small sections. * Magnetic resonance imaging (MRI) of the abdomen. This test uses radio waves and a strong magnetic field to produce images of body tissues and organs. * Ultrasound of the abdomen. This test uses sound waves to create images body tissues and organs. * Blood tests for routine laboratory chemistries, for tests specific to the pancreas, and for genetic studies * 24-hour urine studies After the tests are completed, the doctor will discuss the results with the patient. Patients with a pancreatic tumor that requires surgery will be offered the option of an operation to remove as much tumor as possible. Patients with lesions that are not appropriate for surgery will be asked to return to National Institutes of Health (NIH) for scans and x-rays every year to monitor growth of the lesions. If surgery should become advisable in the future, the option will be discussed at that time. Patients with pancreatic cysts will be asked to return to NIH every 2 years for scans and x-rays to
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2003-04-11 |
| Est. Completion | 2017-11-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062166
The ClinicalTrials.gov registry entry for NCT00062166 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00062166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062166 about?
NCT00062166 is a clinical study titled "Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease". Von Hippel-Lindau disease (VHL) is an inherited cancer syndrome. Patients are at risk for developing pancreatic cysts and tumors. These tumors are more aggressive in some people than in others. To learn more about this disease, its genetic cause and how best to treat it, this study will 1) identify ...
What is the current status of trial NCT00062166?
This trial is currently completed. The enrollment target is 340 participants. The study started on 2003-04-11. Estimated completion is 2017-11-29.
Who is sponsoring clinical trial NCT00062166?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.